Our results provided evidence of the significance of FGB variants in the future genotype-specific risk stratification of CES in AF patients with low CHA2DS2-VaSc score, which should allow improved decision support for the care of these relatively high risk patients. This evidence concerns the gene FGB and atrial fibrillation.